[Form 4] Regions Financial Corp. Insider Trading Activity
Insider purchase reported by a Regions Financial Corp. director. Roger W. Jenkins, identified as a company director, purchased 4,000 shares of Regions Financial Corp. (ticker: RF) on 08/13/2025 at a weighted average price of $25.4764 per share. Following this transaction, Jenkins beneficially owns 6,383 shares. The Form 4 was signed on behalf of the reporting person by Elizabeth H. Townsend as attorney-in-fact on 08/14/2025. The filing lists the transaction code P, indicating a purchase, and discloses that the reported price is the weighted average of multiple trades that ranged from $25.475 to $25.4765.
- Director purchase disclosed: Roger W. Jenkins purchased 4,000 shares, increasing his reported ownership to 6,383 shares.
- Clear transaction detail: Form 4 lists transaction date (08/13/2025), transaction code P, and weighted average price $25.4764.
- None.
Insights
TL;DR: A director purchased 4,000 RF shares, modestly increasing insider ownership to 6,383 shares.
The filing documents a routine open-market purchase by a director, reported under Form 4. The transaction code P and the weighted average price of $25.4764 are consistent with multiple small trades on 08/13/2025. The resulting beneficial ownership of 6,383 shares is a concrete change in holdings but represents a small absolute stake relative to a public bank's outstanding shares. From a financial-analysis standpoint, this is a disclosed insider purchase but not, by itself, materially impactful to Regions' capital structure or share count.
TL;DR: Proper insider reporting visible; transaction executed via attorney-in-fact and disclosed on Form 4.
The Form 4 appears complete for the reported transaction: it names the reporting person as a director, shows the purchase date (08/13/2025), transaction code (P), number of shares acquired (4,000), and beneficial ownership after the trade (6,383). The signature block indicates an attorney-in-fact filed and signed on 08/14/2025, which is acceptable practice when authorized. There are no indications in the filing of derivative transactions, sales, or amendments beyond this disclosure.